Stock listing
Frankfurt:1KA GH Research PLC Aktie
German listing (Frankfurt) of GH Research PLC · home listing NASDAQ:GHRS
Follow GH Research PLC into a list and get an email when it puts out news.
Share price · FWB:1KA
€15.90 EUR -0.30 (-1.9%)
Close on Nov 20, 2026
- Day range
- €15.90 – €16.40 EURNov 20, 2026
- Market cap
- €1.09B EURAt the close on Nov 20, 2026 · price × 68.64M shares outstanding
- 52-week range
- €10.12 – €26.88 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €6,602 EURMedian day 0 shares · 40 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GHRS · Home | $17.53 USD | -0.72 (-3.9%) | 298,833 | $18.32 | $18.32 | $17.29 | $18.25 | Close on Nov 20, 2026 |
| Frankfurt:1KA | €15.90 EUR | -0.30 (-1.9%) | — | €16.40 | €16.40 | €15.90 | €16.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:1KA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €16.17 | -0.591 | -3.5% | €16.00 | €16.40 | €15.94 | 0 | |
| €16.76 | -0.499 | -2.9% | €17.29 | €17.35 | €16.66 | 558 | |
| €17.26 | -0.558 | -3.1% | €17.47 | €17.64 | €16.94 | 558 | |
| €17.82 | -0.196 | -1.1% | €17.71 | €17.86 | €17.71 | 0 | |
| €18.01 | -0.756 | -4.0% | €18.12 | €18.13 | €18.00 | 0 | |
| €18.77 | +0.016 | +0.1% | €18.77 | €18.77 | €18.77 | 614 | |
| €18.75 | +1.231 | +7.0% | €18.38 | €18.85 | €18.38 | 344 | |
| €17.52 | -0.111 | -0.6% | €17.52 | €17.52 | €17.52 | 8,900 | |
| €17.63 | +0.801 | +4.8% | €16.94 | €17.63 | €16.93 | 0 | |
| €16.83 | +0.802 | +5.0% | €15.77 | €16.84 | €15.69 | 0 | |
| €16.03 | -0.358 | -2.2% | €16.03 | €16.03 | €16.03 | 0 | |
| €16.39 | -0.266 | -1.6% | €16.39 | €16.39 | €16.39 | 0 | |
| €16.65 | -0.198 | -1.2% | €16.64 | €16.66 | €16.61 | 0 | |
| €16.85 | +0.636 | +3.9% | €15.97 | €16.88 | €15.93 | 1,829 | |
| €16.22 | -0.127 | -0.8% | €15.96 | €16.24 | €15.90 | 0 | |
| €16.34 | -0.059 | -0.4% | €16.34 | €16.34 | €16.34 | 0 | |
| €16.40 | -0.021 | -0.1% | €16.29 | €16.59 | €16.27 | 0 | |
| €16.42 | -1.147 | -6.5% | €16.42 | €16.42 | €16.42 | 0 | |
| €17.57 | -0.906 | -4.9% | €17.62 | €17.62 | €17.45 | 0 | |
| €18.48 | +0.699 | +3.9% | €18.48 | €18.48 | €18.48 | 0 | |
| €17.78 | -0.637 | -3.5% | €17.78 | €17.78 | €17.78 | 0 | |
| €18.41 | -0.296 | -1.6% | €18.41 | €18.41 | €18.41 | 1,000 | |
| €18.71 | -0.233 | -1.2% | €18.71 | €18.71 | €18.71 | 0 | |
| €18.94 | -1.064 | -5.3% | €19.21 | €19.21 | €18.94 | 0 | |
| €20.01 | -0.028 | -0.1% | €20.01 | €20.01 | €20.01 | 0 | |
| €20.03 | -0.007 | 0.0% | €20.03 | €20.16 | €19.84 | 390 | |
| €20.04 | -1.32 | -6.2% | €20.27 | €20.42 | €19.85 | 0 | |
| €21.36 | +1.223 | +6.1% | €21.36 | €21.36 | €21.36 | 0 | |
| €20.14 | -0.33 | -1.6% | €20.14 | €20.14 | €20.14 | 0 | |
| €20.47 | -0.064 | -0.3% | €20.47 | €20.47 | €20.47 | 500 | |
| €20.53 | -0.453 | -2.2% | €20.81 | €20.88 | €20.48 | 0 | |
| €20.99 | -1.346 | -6.0% | €22.37 | €22.41 | €20.98 | 1,249 | |
| €22.33 | -1.516 | -6.4% | €23.83 | €23.87 | €22.21 | 0 | |
| €23.85 | -0.385 | -1.6% | €23.85 | €23.85 | €23.85 | 1,240 | |
| €24.23 | -0.291 | -1.2% | €24.23 | €24.23 | €24.23 | 0 | |
| €24.52 | +0.599 | +2.5% | €24.56 | €24.62 | €24.47 | 0 | |
| €23.92 | +0.372 | +1.6% | €23.92 | €23.92 | €23.92 | 0 | |
| €23.55 | +0.277 | +1.2% | €23.55 | €23.55 | €23.55 | 560 | |
| €23.28 | -0.735 | -3.1% | €23.45 | €23.65 | €23.10 | 500 | |
| €24.01 | +0.662 | +2.8% | €23.21 | €24.17 | €23.10 | 0 | |
| €23.35 | +0.018 | +0.1% | €23.35 | €23.35 | €23.35 | 604 | |
| €23.33 | -0.054 | -0.2% | €23.33 | €23.33 | €23.33 | 500 | |
| €23.38 | -0.134 | -0.6% | €23.38 | €23.38 | €23.38 | 0 | |
| €23.52 | -0.186 | -0.8% | €23.52 | €23.52 | €23.52 | 0 | |
| €23.70 | +0.118 | +0.5% | €23.70 | €23.70 | €23.70 | 0 | |
| €23.59 | -0.327 | -1.4% | €23.59 | €23.59 | €23.59 | 0 | |
| €23.91 | +0.829 | +3.6% | €23.91 | €23.91 | €23.91 | 0 | |
| €23.08 | +0.479 | +2.1% | €23.08 | €23.08 | €23.08 | 0 | |
| €22.61 | -0.998 | -4.2% | €22.61 | €22.61 | €22.61 | 0 | |
| €23.60 | -0.597 | -2.5% | €23.60 | €23.60 | €23.60 | 0 | |
| €24.20 | -0.057 | -0.2% | €24.20 | €24.20 | €24.20 | 206 | |
| €24.26 | -0.095 | -0.4% | €24.26 | €24.26 | €24.26 | 0 | |
| €24.35 | +0.751 | +3.2% | €24.35 | €24.35 | €24.35 | 0 | |
| €23.60 | -0.551 | -2.3% | €23.60 | €23.60 | €23.60 | 0 | |
| €24.15 | +0.346 | +1.5% | €24.15 | €24.15 | €24.15 | 0 | |
| €23.81 | -1.135 | -4.6% | €23.81 | €23.81 | €23.81 | 200 | |
| €24.94 | -0.397 | -1.6% | €24.94 | €24.94 | €24.94 | 0 |
- Ticker
- Frankfurt:1KA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Nov 13, 2026
Corporate Update (November 2026)
Corporate update · 19 slides
Latest news
GH Research Announces Publication of Phase 2a Postpartum Depression Results
Jun 4, 2026
Closed €20.55 (+1.0%) on Jun 4, 2026
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Closed €18.03 (+1.4%) on May 14, 2026
GH Research Announces Pricing of $117.5 Million Underwritten Offering
Apr 29, 2026
Closed €16.61 (+2.5%) on Apr 29, 2026
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
Apr 20, 2026
Closed €18.53 (+26.1%) on Apr 20, 2026
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
Mar 25, 2026
Closed €11.10 (+1.0%) on Mar 25, 2026
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
Mar 5, 2026
Closed €13.34 (-0.6%) on Mar 5, 2026
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
Jan 5, 2026
Closed €13.85 (+25.6%) on Jan 5, 2026
GH Research to Announce IND Status for GH001
Jan 2, 2026
Closed €11.03 (+7.0%) on Jan 2, 2026
GH Research PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 42 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 37 decks · latest Nov 13, 2026
Where GH Research PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GHRS · Home listing | NASDAQ | United States | USD |
| gettex:1KA | gettex | Germany | EUR |
| Frankfurt:1KA · This page | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3CUAZ | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3CUAZ | LS Exchange | Germany | EUR |
| Tradegate:1KA | Tradegate | Germany | EUR |
| BOATS:GHRS | BOATS | United States | USD |
| Dusseldorf:1KA | Dusseldorf | Germany | EUR |
| Munich:1KA | Munich | Germany | EUR |
| Stuttgart:1KA | Stuttgart | Germany | EUR |
Valuation
Price/book 3.4× against a median of 3.2×: 5th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $841.0M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.28
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204 | US$1.17B | US$1.01B | n/a | 36.1× | n/a | 3.9× | −53.3% | 0.0× | n/a |
| OPKO Health, Inc. · NASDAQ:OPK | US$1.17B | US$1.26B | n/a | 2.5× | n/a | 1.0× | −29.5% | 0.4× | 0.90 |
| Median of the others | US$1.22B | US$899.0M | 0.9× | 21.7× | 309× | 3.2× | −41.4% | 0.1× | 1.35 |
Forecasts
7 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 42.89 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.14 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Velichka Valcheva | Chief Executive Officer |
| Aaron Cameron | Chief Operating Officer |
| Julie Ryan | Vice President, Finance |
| Florian Schönharting | Chairman of the Board & Co-Founder |
| Magnus Halle | Managing Director, Ireland & Co-Founder |
| Vanina Popova | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Florian Schönharting | Chairman of the Board & Co-Founder |
| Dermot Hanley | Director |
| Duncan Moore | Director |
| Michael Forer | Vice Chairman of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 13, 2026 · Before open | +3.3% |
| Q2 2026 | Aug 6, 2026 · Before open | +5.2% |
| Q1 2026 | May 14, 2026 · Before open | +1.5% |
| Q4 2025 | Feb 26, 2026 | −5.7% |
| Q3 2025 | Nov 6, 2025 · Before open | −1.3% |
| Q2 2025 | Aug 7, 2025 · Before open | −0.4% |
| Q1 2025 | May 8, 2025 · Before open | +5.2% |
| Q4 2024 | Feb 27, 2025 | −7.7% |
| Q3 2024 | Nov 14, 2024 · Before open | −2.9% |
| Q2 2024 | Sep 3, 2024 | −19.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 3, 2024 · Before open | +4.4% |
| Q4 2023 | Feb 29, 2024 · Before open | +7.9% |
| Q3 2023 | Nov 9, 2023 · After close | +3.3% |
| Q2 2023 | Aug 23, 2023 · Before open | −1.9% |
| Q1 2023 | May 11, 2023 · Before open | +3.6% |
| Q4 2022 | Mar 2, 2023 · Before open | −2.7% |
| Q3 2022 | Nov 10, 2022 · Before open | +7.0% |
| Q2 2022 | Aug 23, 2022 · Before open | +5.3% |
| Q1 2022 | May 18, 2022 · Before open | −10.0% |
| Q4 2021 | Mar 28, 2022 · Before open | +1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 19 slides | Nov 13, 2026 |
| Investor Presentation (August 2026) | Investor deck | 19 slides | Aug 6, 2026 |
| Investor Presentation (May 2026) | Investor deck | 17 slides | May 14, 2026 |
| Investor Presentation (March 2026) | Investor deck | 17 slides | Mar 5, 2026 |
| ACNP 2026 | Conference | 46 slides | Jan 15, 2026 |
| Technical Presentation (January 2026) | Technical | 20 slides | Jan 13, 2026 |
| Investor Presentation (January 2026) | Investor deck | 17 slides | Jan 5, 2026 |
| ACNP 2026 Mini Panel | Conference | 43 slides | January 2026 |
| ESG Presentation (December 2025) | Sustainability | 6 slides | Dec 3, 2025 |
| Investor Presentation (November 2025) | Investor deck | 14 slides | Nov 6, 2025 |
All 37 decks
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares Announced: about US$117.5M · US$18 a share · Stifel +4 Dealers: Stifel (lead), Cantor (lead), RBC Capital Markets (lead), Canaccord Genuity (co-lead), Citizens Capital Markets (co-lead) Buyers: Lynx1 Capital Management (initiated the offering); Deep Track Capital; Foresite Capital | Apr 29, 2026 |
| Public offering of ordinary shares Update: about US$150M · US$15 a share · Cantor +4 Dealers: Cantor (lead), Stifel (lead), RBC Capital Markets (lead), Canaccord Genuity (co-lead), Citizens JMP (co-lead) | Feb 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jun 24, 2021.
- Price
- US$16.00 a share
- Shares offered
- 10,000,000 ordinary shares
- Offering size
- US$160 million
- Underwriters' option
- Up to 1,499,999 more shares
- Listing
- GHRS on the Nasdaq Global Market
- Underwriters
- Cowen, Stifel, Canaccord Genuity, JMP Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 20, 2021 |
| Filed publicly | Jun 4, 2021 |
| Amended once | Jun 21, 2021 |
| Shares registered with an exchange | Jun 22, 2021 |
| Declared effective by the SEC | Jun 24, 2021 |
| Final prospectus, with the price | Jun 28, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 28, 2021 |
| EFFECT · Notice that a registration is effective | Jun 24, 2021 |
| F-1MEF · Registration of more shares for the same offering | Jun 24, 2021 |
| CERT · Exchange's certificate of listing | Jun 23, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 21, 2021 |
| F-1/A · Registration statement, amended | Jun 21, 2021 |
| UPLOAD · Letter from the SEC | Jun 18, 2021 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 4, 2021 |
| F-1 · Registration statement | Jun 4, 2021 |
| UPLOAD · Letter from the SEC | May 18, 2021 |
| DRS · Draft registration statement | Apr 20, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 335.0K | 315.0K | 315.0K | 47.0K | 19.0K | ||
| Gross profit | -335.0K | -315.0K | -315.0K | -47.0K | -19.0K | ||
| Research and development | 38.8M | 35.0M | 29.8M | 20.5M | 8.55M | 338.0K | 296.0K |
| Selling, general and administrative | 22.0M | 15.3M | 11.4M | 10.1M | 6.55M | 108.0K | 14.0K |
| Operating income | -60.7M | -50.3M | -41.2M | -30.6M | -15.1M | -446.0K | -310.0K |
| Depreciation and amortization | 335.0K | 315.0K | 315.0K | 47.0K | 19.0K | 0 | 0 |
| EBITDA | -60.4M | -50.0M | -40.9M | -30.5M | -15.1M | -446.0K | -310.0K |
| Interest expense | 463.0K | 717.0K | 63.0K | 0 | 9.00K | 0 | 0 |
| Income before tax | -48.3M | -39.0M | -35.6M | -22.5M | -9.20M | -446.0K | -310.0K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -48.3M | -39.0M | -35.6M | -22.5M | -9.20M | -446.0K | -310.0K |
| Earnings per share, basic | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 | -0.02 | -0.01 |
| Earnings per share, diluted | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 | -0.02 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 246.3M | 100.8M | 78.4M | 166.0M | 276.8M | 5.89M | 498.0K |
| Short-term investments | 34.5M | 48.5M | 83.1M | 0 | |||
| Receivables | 1.29M | 1.73M | 178.0K | 90.0K | 48.0K | 6.00K | |
| Inventory | -178.0K | -90.0K | 3.01M | -6.00K | |||
| Current assets | 286.0M | 154.2M | 164.1M | 168.5M | 279.8M | 5.91M | 504.0K |
| Property, plant and equipment | 620.0K | 748.0K | 1.07M | 97.0K | 82.0K | 0 | |
| Total assets | 288.2M | 188.3M | 226.3M | 254.4M | 279.9M | 5.91M | 504.0K |
| Accounts payable | 3.77M | 3.74M | 3.49M | 1.87M | 883.0K | 1.00K | 93.0K |
| Current liabilities | 8.38M | 8.95M | 6.70M | 4.55M | 2.75M | 246.0K | 104.0K |
| Total debt | 0 | 0 | 0 | 0 | 0 | ||
| Total liabilities | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M | 246.0K | 104.0K |
| Shareholders' equity | 279.7M | 179.0M | 219.0M | 249.8M | 277.2M | 5.67M | 400.0K |
| Shares outstanding | 61.0M | 52.0M | 52.0M | 52.0M | 52.0M | 30.4M | 28.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -43.6M | -42.3M | -33.3M | -26.2M | -15.3M | -330.0K | -289.0K |
| Capital spending | -121.0K | -49.0K | -100.0K | -67.0K | -104.0K | 0 | 0 |
| Free cash flow | -43.7M | -42.3M | -33.4M | -26.3M | -15.4M | -330.0K | -289.0K |
| Cash from investing | 46.2M | 65.1M | -54.1M | -84.7M | -104.0K | 0 | -104.0K |
| Cash from financing | 139.7M | -304.0K | -204.0K | 0 | 286.4M | 5.50M | 797.0K |
| Change in cash | 142.3M | 22.5M | -87.6M | -110.9M | 271.1M | 5.17M | 508.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 13, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 203 filings. Open Filings
Cap table
Built by 6ix from GH Research PLC’s releases · as of Apr 29, 2026
- Common shares
- 68,642,287
- Fully diluted
- 68,642,287
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 68,642,287 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 68,642,287 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Duncan Moore Other companies: ASP Isotopes Inc. (Partner at East West Capital Partners · Since at least Nov 9, 2022); Allarity Therapeutics, Inc. (Director · Dec 20, 2021 – Dec 20, 2021 · Past) | Director · Since at least Mar 18, 2026 |
| Aaron Cameron | Chief Operating Officer · Since at least Mar 18, 2026 |
| Dermot Hanley | Director · Since at least Mar 18, 2026 |
| Florian Schönharting | Chairman of the Board & Co-Founder · Since at least Apr 1, 2026 |
| Julie Ryan | Vice President, Finance · Since at least Mar 18, 2026 |
| Magnus Halle | Managing Director, Ireland & Co-Founder · Since at least Mar 18, 2026 |
| Michael Forer | Vice Chairman of the Board · Since at least Mar 18, 2026 |
| Vanina Popova | Chief Development Officer · Since at least Nov 13, 2026 |
| Velichka Valcheva | Chief Executive Officer · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about GH Research PLC.